NPM-ALK-dependent BCL2A1 gene expression

Stable Identifier
Reaction [BlackBoxEvent]
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

BCL2A1 was identified as a transcriptional target of the oncogenic NPM-ALK fusion protein through ALK knockdown and inhibition studies. BCL2A1 is a BCL2 family member that encodes an anti-apoptotic protein that, along with BAX2, is preferentially expressed by ALK signaling. shRNA-mediated knockdown of BCL2A1 promotes apoptosis, highlighting a critical role for BCL2A1 in mediating cellular survival (Piva et al, 2006; reviewed in Hallberg and Palmer, 2013).

Literature References
PubMed ID Title Journal Year
17111047 Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes

Chiarle, R, Piva, R, Inghirami, G, Ruggeri, BA, Boccalatte, F, Cheng, M, Palestro, G, Costa, G, Lombardi, L, Pellegrino, E, Neri, A, Agnelli, L, Mattioli, M

J Clin Invest 2006
24060861 Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

Palmer, RH, Hallberg, B

Nat. Rev. Cancer 2013
This event is regulated
Name Identifier Synonyms
anaplastic large cell lymphoma DOID:0050744
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cite Us!